Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:44:41 ON 06 MAR 2008

=> file reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                             ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 07:44:54 ON 06 MAR 2008

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 MAR 2008 HIGHEST RN 1006657-22-2
DICTIONARY FILE UPDATES: 4 MAR 2008 HIGHEST RN 1006657-22-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10573484.str



chain nodes :
7 17 18 19 20 21 29 31 32 33

ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 23 24 25 26 27 28
chain bonds :
2-18 3-20 4-21 5-19 6-7 7-12 11-17 29-31 29-32 29-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 9-13 10-11 10-16 11-12 13-14
14-15 15-16 23-24 23-28 24-25 25-26 26-27 27-28
exact/norm bonds :
4-21 6-7 7-12 8-9 8-12 10-11 11-12 29-31 29-32 29-33
exact bonds :
2-18 3-20 5-19 11-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-16 13-14 14-15 15-16 23-24 23-28
24-25 25-26 26-27 27-28
isolated ring systems :
containing 1 : 8 : 23 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:CLASS
30:Atom 31:CLASS 32:CLASS 33:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 07:45:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       36 TO ITERATE

100.0% PROCESSED       36 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          360 TO     1080
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:45:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      605 TO ITERATE

100.0% PROCESSED      605 ITERATIONS                                38 ANSWERS
SEARCH TIME: 00.00.01

L3           38 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.36     178.57

FILE 'CAPLUS' ENTERED AT 07:45:35 ON 06 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Mar 2008  VOL 148 ISS 10
FILE LAST UPDATED: 5 Mar 2008  (20080305/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4           3 L3

=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300447 CAPLUS
DOCUMENT NUMBER: 142:373838
TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030771	A1	20050407	WO 2004-EP52378	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276015	A1	20050407	AU 2004-276015	20040930
CA 2540083	A1	20050407	CA 2004-2540083	20040930
EP 1675854	A1	20060705	EP 2004-787263	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856491	A	20061101	CN 2004-80027592	20040930
BR 2004014972	A	20061107	BR 2004-14972	20040930
JP 2007507467	T	20070329	JP 2006-530264	20040930
NO 2006001344	A	20060324	NO 2006-1344	20060324
MX 2006PA03349	A	20060608	MX 2006-PA3349	20060324
US 2007043073	A1	20070222	US 2006-573484	20060324
IN 2006MN00475	A	20070316	IN 2006-MN475	20060424

PRIORITY APPLN. INFO.: EP 2003-22053 A 20031001
WO 2004-EP52378 W 20040930

OTHER SOURCE(S): CASREACT 142:373838; MARPAT 142:373838
GI



I



II

AB Title compds. I [R1 = H, alkyl; R2 = H, alkyl; R3 = H, halo; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with N,N-dimethyl-4-bromobenzenesulfonamide. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 7.45 up to 7.86 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849357-47-7P 849357-48-8P 849357-49-9P
849357-50-2P 849357-51-3P 849357-52-4P
849357-54-6P 849357-55-7P 849357-56-8P
849357-57-9P 849357-58-0P 849357-59-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849357-47-7 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 849357-48-8 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-

imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-49-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849357-50-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-51-3 CAPLUS
CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-52-4 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 849357-54-6 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-55-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849357-56-8 CAPLUS
CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-57-9 CAPLUS
CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849357-58-0 CAPLUS
CN Benzenesulfonamide, N,N-diethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-59-1 CAPLUS
CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300446 CAPLUS

DOCUMENT NUMBER: 142:373837

TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030770	A1	20050407	WO 2004-EP52377	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276014	A1	20050407	AU 2004-276014	20040930
CA 2540243	A1	20050407	CA 2004-2540243	20040930
EP 1670796	A1	20060621	EP 2004-787262	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856495	A	20061101	CN 2004-80027833	20040930
BR 2004014933	A	20061107	BR 2004-14933	20040930
JP 2007507466	T	20070329	JP 2006-530263	20040930
NO 2006001317	A	20060323	NO 2006-1317	20060323
MX 2006PA03351	A	20060608	MX 2006-PA3351	20060324
US 2006293302	A1	20061228	US 2006-573202	20060324
US 7279488	B2	20071009		
IN 2006MN00362	A	20070615	IN 2006-MN362	20060331
US 2008021039	A1	20080124	US 2007-905033	20070927

PRIORITY APPLN. INFO.:	EP 2003-22046	A	20031001
	WO 2004-EP52377	W	20040930
	US 2006-573202	A1	20060324

OTHER SOURCE(S): CASREACT 142:373837; MARPAT 142:373837

GI



I



II

AB Title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkoxyalkyl, hydroxyalkyl, etc.; R3 = alkyl, CF3, completely or predominantly F-substituted alkoxy, etc.; R1 and R2 together = (un)saturated-, (un)substituted-nitrogen heterocycle; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 1-(4-bromo-benzene-sulfonyl)-4-methyl-piperazine. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 6.51 up to 7.89 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849530-98-9P 849531-00-6P 849531-02-8P
849531-04-0P 849531-06-2P 849531-08-4P
849531-10-8P 849531-12-0P 849531-14-2P
849531-16-4P 849531-18-6P 849531-20-0P
849531-50-6P 849531-58-4P 849531-60-8P
849531-62-0P 849531-64-2P 849531-66-4P
849531-68-6P 849531-70-0P 849531-72-2P
849531-74-4P 849531-80-2P 849531-82-4P
849531-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849530-98-9 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-00-6 CAPLUS
CN Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-02-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 849531-04-0 CAPLUS
CN Benzenesulfonamide, N-cyclohexyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-06-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 849531-08-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 849531-10-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N,3-trimethyl- (9CI) (CA INDEX NAME)



RN 849531-12-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 849531-14-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-16-4 CAPLUS
CN Benzenesulfonamide, N-(2-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-18-6 CAPLUS
CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-20-0 CAPLUS
CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849531-50-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 849531-58-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-60-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 849531-62-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-64-2 CAPLUS
CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849531-66-4 CAPLUS
CN Benzenesulfonamide, N-(2-fluoro-4-methylphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-68-6 CAPLUS
CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-70-0 CAPLUS
CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849531-72-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-74-4 CAPLUS
CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-80-2 CAPLUS
CN Benzenesulfonamide, N,N-bis(2-methoxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-82-4 CAPLUS
CN Benzenesulfonamide, N-cyclobutyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-84-6 CAPLUS
CN Benzenesulfonamide, N-cyclopropyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:777790 CAPLUS

DOCUMENT NUMBER: 139:292156

TITLE: Preparation of alkoxypyridines as inducible nitric oxide synthase (iNOS) inhibitors

INVENTOR(S): Boer, Rainer; Marx, Degenhard; Eltze, Manfrid; Klein, Thomas; Nave, Ruediger; Graedler, Ulrich; Fuchss, Thomas; Barsig, Johannes; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080607	A1	20031002	WO 2003-EP3076	20030325
W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2480385	A1	20031002	CA 2003-2480385	20030325
AU 2003226706	A1	20031008	AU 2003-226706	20030325
EP 1490366	A1	20041229	EP 2003-744851	20030325
EP 1490366	B1	20080123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008785	A	20050111	BR 2003-8785	20030325
CN 1642955	A	20050720	CN 2003-806917	20030325
JP 2005525388	T	20050825	JP 2003-578361	20030325
NZ 535959	A	20060526	NZ 2003-535959	20030325
AT 384722	T	20080215	AT 2003-744851	20030325
IN 2004MN00462	A	20050218	IN 2004-MN462	20040820
MX 2004PA09283	A	20050125	MX 2004-PA9283	20040923
US 2005171125	A1	20050804	US 2004-509396	20040924
US 7138399	B2	20061121		
ZA 2004007766	A	20060628	ZA 2004-7766	20040927
NO 2004004633	A	20041223	NO 2004-4633	20041027
HK 1078850	A1	20071109	HK 2005-110611	20051123
PRIORITY APPLN. INFO.:			EP 2002-7049 A	20020327
			WO 2003-EP3076 W	20030325

OTHER SOURCE(S): MARPAT 139:292156

GI



I



II

AB Title compds. I [wherein R1 = alkoxy; A = alkylene; B = (un)substituted 3H-imidazo[4,5-b]pyridin-2-yl, 9H-purin-8-yl; their salts, N-oxides, and salts of the N-oxides] were prepared as inducible NO-synthase (iNOS) inhibitor for treatment of acute inflammatory diseases and chronic inflammatory diseases of peripheral organs and central nervous system (CNS). For example, II (m.p. = 116-117°) was prepared by cyclocondensation of Me 3-(4-methoxypyridin-2-yl)propionate (preparation given) with 2,3-diaminopyridine in the presence of polyphosphoric acid at 160° for 1 h. Selected invention compds. inhibited iNOS with -logIC50 (M) in the range of 7.03-7.55. Thus, I and their pharmaceutical compns. are useful for treating acute inflammatory diseases, chronic inflammatory diseases of peripheral organs and CNS and cancer (no data).

IT 608880-84-8P, N-[4-[2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inducible NO-synthase inhibitor; preparation of alkoxypyridines as inducible NO-synthase inhibitors)

RN 608880-84-8 CAPLUS

CN Benzenesulfonamide, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 07:44:41 ON 06 MAR 2008)

     FILE 'REGISTRY' ENTERED AT 07:44:54 ON 06 MAR 2008
L1             STRUCTURE UPLOADED
L2           1 S L1
L3          38 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 07:45:35 ON 06 MAR 2008
L4           3 S L3 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      18.75     197.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.40      -2.40

STN INTERNATIONAL LOGOFF AT 07:48:21 ON 06 MAR 2008
```